Advertisement

Topics

CytRx Company Profile

04:32 EST 23rd November 2017 | BioPortfolio

CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. CytRx's small molecule drug candidates provide cellular protection by activating "molecular chaperone" proteins that can repair or degrade proteins that are believed to cause many diseases. "Molecular chaperones" represent a therapeutic development platform from which CytRx may derive several drugs that address large markets and unmet medical needs. CytRx initiated a Phase II clinical trial with arimoclomol in ALS in September 2005. The initial Phase II trial included 84 patients treated at 10 clinical sites in the United States with initial results expected in 4Q '06. The FDA has granted Fast Track and Orphan Drug designation for arimoclomol in ALS. CytRx is a world leader in developing products based on advanced RNAi technology primarily for the human health care market. RNAi has been shown to effectively silence a targeted disease-causing gene within a living cell. CytRx has a broad based strategic alliance with the University of Massachusetts Medical School (UMMS) which has given the company unparalleled access to RNAi technology and serves as a broad platform for a myriad of drug discovery applications including obesity, type 2 diabetes, ALS (Lou Gehrig's disease), and CMV (cytomegalovirus). Additionally, CytRx has a sponsored research program with Massachusetts General Hospital, Harvard's teaching hospital, to develop therapies to treat ALS using RNAi. CytRx has also licensed from the UMMS the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology. The HIV vaccine is based on a unique cocktail of human HIV-1 primary isolates from several genetic subtypes of HIV. Phase I clinical results announced in July 2006 indicate that the DNA + protein boost HIV vaccine, based on 5 known primary human HIV strains, was well tolerated and produced potent antibody responses with neutralizing activity against multiple HIV viral strains. This clinical program, was funded by a $16 million NIAID grant, was being conducted by CytRx, University of Massachusetts Medical School (UMMS) and Advanced BioScience Laboratories (ABL).

Location

11726 San Vicente Blvd
Suite 650
Los Angeles
California
90049
United States of America

Contact

Phone: (310) 826-5648
Fax: (310) 826-6139
Email: mwachs@ceocast.com


News Articles [33 Associated News Articles listed on BioPortfolio]

CytRx Reports Third Quarter 2017 Financial Results

"The third quarter of 2017 was transformative for CytRx," said Steven A. Kriegsman, CytRx's Chairman and CEO. "We executed a global strategic licensing transaction Read more...

STAT Plus: His stock has tanked, his drugs have failed, and CytRx chief Steve Kriegsman knows who’s at fault: Me

If you bought $1,000 worth of CytRx stock a decade ago, it's worth $10. Yet its CEO has made more than $10 million. He blames me for his company's woes.

CytRx Announces Strategic Realignment of Clinical Development Team

"Dr. Margaret Hurley, and her world-class team, are recognized experts in drug development and regulatory strategy and have provided CytRx with invaluable guidance and Read more...

CytRx Corporation Announces Receipt of NASDAQ Listing Determination

CytRx plans to request a hearing before the NASDAQ Hearings Panel (the "Panel"), which will stay any delisting action pending the issuance of the Panel's Read more...

NantCell gets exclusive aldoxorubicin rights from CytRx

CytRx Corp. grated NantCell LLC exclusive global rights to aldoxorubicin, a DNA topoisomerase inhibitor in late-stage trials for various solid tumors.

CytRx Highlights Inclusion Of Aldoxorubicin In Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell

LOS ANGELES, Oct. 12, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today highlightedthat aldoxorubicin licensee ...

CytRx Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 12062017] Prices from USD $350

CytRx Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's CytRx Corporation Mergers Acquisitions MA, Partnerships Alliances and Investments report...

CytRx: SCLC Study Still Breathing?

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

CytRx

CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small mole...

CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline include...

More Information about "CytRx" on BioPortfolio

We have published hundreds of CytRx news stories on BioPortfolio along with dozens of CytRx Clinical Trials and PubMed Articles about CytRx for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CytRx Companies in our database. You can also find out about relevant CytRx Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record